Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, INTERNATIONAL STEM CELL CORPORATION reported revenue of $9M, up 0.2% year over year. Operating margin was -2.9% and net margin -4.6%, on a free-cash-flow margin of -0.4% with capital expenditure at 0.5% of revenue. Every figure is computed directly from ISCO's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $9M | -2.9% | -4.6% |
| FY2024 | $9M | -0.7% | -2.3% |
| FY2023 | $8M | -8.5% | -1.7% |
| FY2022 | $8M | -2.2% | -4.0% |
| FY2021 | $7M | -26.8% | -12.5% |
How does ISCO compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.